Reaction

Blood Blister reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,093 reports · 69 co-occurring drugs

As of the last recalculation, Blood Blister appears in 3,093 FAERS reports alongside 69 co-occurring drug terms. The strongest observed disproportionality signal is IBRUTINIB (PRR 18.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ibrutinib	211	18.8	18.8
Romiplostim	30	13.5	13.6
Fondaparinux Sodium	13	10.9	10.9
Psyllium Husk	12	8.2	8.2
Febuxostat	20	8.1	8.1
Acalabrutinib	13	7.2	7.3
Clobetasol Propionate Ointment Usp, 0.05%	11	7.2	7.2
Clobetasol Propionate	11	7.2	7.2
Cyclobenzaprine Hydrochloride	9	6.8	6.8
Prednisolone Acetate	10	6.5	6.5
Imatinib	17	6.5	6.5
Rivaroxaban	180	6.1	6.1
Terazosin Hydrochloride	8	6.1	6.1
Enoxaparin Sodium	51	6.0	6.1
Primidone	9	6.0	6.0
Eltrombopag Olamine	20	5.9	5.9
Sorafenib	18	5.9	5.9
Imatinib Mesylate	24	5.8	5.8
Niraparib	19	5.8	5.8
Pravastatin Sodium	16	5.5	5.5
Oxybutynin Chloride	7	5.4	5.4
Tranexamic Acid	7	5.3	5.3
Bosutinib	7	5.3	5.3
Ticagrelor	24	5.1	5.1
Sunitinib Malate	29	5.0	5.0
Dutasteride	6	5.0	5.0
Lovastatin	18	4.7	4.7
Niacin	8	4.6	4.6
Biotin	21	4.6	4.6
Mupirocin	9	4.5	4.5
Isosorbide Dinitrate	13	4.5	4.5
Thyroid, Porcine	7	4.4	4.4
Mupirocin Calcium	9	4.4	4.4
Heparin Sodium	9	4.4	4.4
Ropinirole	10	4.4	4.4
Warfarin	80	4.3	4.3
Epoprostenol	8	4.1	4.1
Febuxostat Tablets 40 Mg	6	4.0	4.0
Febuxostat Tablets 80 Mg	6	4.0	4.0
Emicizumab	7	3.8	3.8
Desoximetasone	10	3.5	3.5
Avapritinib	6	3.3	3.3
Mesna Injection	4	3.3	3.3
Nilotinib	14	3.2	3.2
Mesna	4	3.2	3.2
Dabigatran Etexilate Mesylate	34	3.2	3.2
Tiotropium Bromide Inhalation Spray	5	3.0	3.0
Dabigatran Etexilate	34	3.0	3.0
Ruxolitinib	31	2.9	2.9
Riociguat	14	2.9	2.9
Cabozantinib	20	2.8	2.8
Peginterferon Alfa-2A	22	2.8	2.8
Nintedanib	12	2.6	2.6
Dofetilide	4	2.6	2.6
Teriparatide	42	2.5	2.5
Abaloparatide	11	2.5	2.5
Abiraterone Acetate	15	2.5	2.5
Glycerin, Lidocaine	5	2.4	2.4
Venetoclax	21	2.3	2.3
Docosanol	5	2.3	2.3
Azacitidine For	6	2.2	2.2
Azacitidine	9	2.0	2.0
Encorafenib	3	2.0	2.0
Sarilumab	7	1.8	1.8
Diroximel Fumarate	3	1.7	1.7
Lifitegrast	3	1.2	1.2
Dupilumab	82	1.1	1.1
Evolocumab	21	0.9	0.9
Nirmatrelvir And Ritonavir	6	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.